GeneDx Reports Q4 and 2024 Financial Results, Provides 2025 Guidance
GeneDx Reports Q4 and 2024 Financial Results, Provides 2025 Guidance GeneDx Holdings Corp. (Nasdaq: WGS), a leader in genomic testing for improved health outcomes, reported its financial results for the fourth quarter and full year of 2024. The company highlighted…
Galderma’s Nemluvio® (Nemolizumab) Approved for Atopic Dermatitis and Prurigo Nodularis in the UK and Switzerland
Galderma’s Nemluvio® (Nemolizumab) Approved for Atopic Dermatitis and Prurigo Nodularis in the UK and Switzerland Galderma has announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Swissmedic have granted marketing authorization for Nemolizumab, a monoclonal antibody…
CancerX Unveils 2025 Accelerator to Propel Oncology Innovation
CancerX Unveils 2025 Accelerator to Propel Oncology Innovation CancerX, a public-private partnership aimed at accelerating cancer innovation, has announced the launch of its 2025 Accelerator cohort. This year’s group includes a remarkable selection of digital health and artificial intelligence startups…
ICC Tribunal Rules in Favor of AOP Health in BESREMi® Arbitration Case
ICC Tribunal Rules in Favor of AOP Health in BESREMi® Arbitration Case An International Chamber of Commerce (ICC) tribunal has issued a partial final award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in an ongoing legal dispute with…
Pneuma Respiratory Enhances Inhaled Therapies for Better Respiratory Health
Pneuma Respiratory Enhances Inhaled Therapies for Better Respiratory Health Pneuma Respiratory, a leading med-tech and pharmaceutical company, is pioneering innovative solutions in inhaled respiratory therapeutics aimed at transforming respiratory care. With a focus on treating smoking-related lung conditions, Pneuma is…
Cellistic Unveils Allo Chassis™: Immune-Cloaked iPSC Cell Lines for Cost-Effective Cell Therapy
Cellistic Unveils Allo Chassis™: Immune-Cloaked iPSC Cell Lines for Cost-Effective Cell Therapy Cellistic, a leader in iPSC-based off-the-shelf cell therapy development and manufacturing services, has introduced its innovative Allo Chassis™—a new line of immune-cloaked iPSC cell lines derived from CD34+…
InnoCare Announces Phase III Study Approval of ICP-248 and Orelabrutinib for CLL/SLL in China
InnoCare Announces Phase III Study Approval of ICP-248 and Orelabrutinib for CLL/SLL in China InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focused on developing therapies for cancer and autoimmune diseases, has announced that the Center for Drug…
BioIntelliSense Teams Up with Hicuity Health for Scalable Continuous Patient Monitoring
BioIntelliSense Teams Up with Hicuity Health for Scalable Continuous Patient Monitoring BioIntelliSense, a leader in continuous health monitoring and clinical intelligence, has announced a strategic partnership with Hicuity Health, a leading provider of tech-enabled virtual care services. This collaboration aims…
Abridge Secures $250M Series D, Unveils New Contextual Reasoning Engine for Healthcare
Abridge Secures $250M Series D, Unveils New Contextual Reasoning Engine for Healthcare Abridge, a leader in generative AI for clinical conversations, has secured a $250 million Series D funding round. This milestone comes as the company surpasses 100 deployments across…
FDA Approves GSK’s PENMENVY 5-in-1 Meningococcal Vaccine
FDA Approves GSK’s PENMENVY 5-in-1 Meningococcal Vaccine GSK plc (LSE/NYSE: GSK) has announced that the U.S. Food and Drug Administration (FDA) has approved its PENMENVY vaccine (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged…
LimmaTech Begins Phase 1 Trial of Staphylococcus aureus Vaccine LBT-SA7
LimmaTech Begins Phase 1 Trial of Staphylococcus aureus Vaccine LBT-SA7 LimmaTech Biologics AG, a clinical-stage biotech company focused on developing vaccines for life-threatening diseases, announced the vaccination of the first participants in a Phase 1 controlled study of its multivalent…
UK’s EDX Medical Develops New ‘Super Test’ for Prostate Cancer
UK’s EDX Medical Develops New ‘Super Test’ for Prostate Cancer Scientists in Cambridge have created a groundbreaking new ‘super test’ for prostate cancer, aiming to transform the way the disease is screened and diagnosed. This innovative test is designed to…